Efficacy of ipilimumab 3 mg/kg following progression on low-dose ipilimumab in metastatic melanoma

Julia Lai-Kwon,Sarah Jacques,Matteo Carlino,Naima Benannoune,Caroline Robert,Clara Allayous,Barouyr Baroudjian,Celeste Lebbe,Lisa Zimmer,Zeynep Eroglu,Turkan Ozturk Topcu,Florentia Dimitriou,Andrew Haydon,Serigne N. Lo,Alexander M. Menzies,Georgina V. Long

European Journal of Cancer（2023）

引用 1|浏览37

暂无评分

摘要

•Ipilimumab 3 mg/kg after recurrence/progression on low-dose ipilimumab (IPI) has clinical activity.•The response rate was 9/36 (25%).•In primary resistance to low-dose IPI, the response rate was 6/20 (30%).•In acquired resistance to low-dose IPI, the response rate was 3/16 (18.5%).•This provides further evidence of the dose–efficacy relationship for IPI.

查看译文

关键词

Melanoma,Immunotherapy,Ipilimumab,Alternative dosing

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要